by Wu Zhou, Zhanguo Chen, Wangqiang Hu, Mo Shen, Xiaoxia Zhang, Chengdi Li, Zhiliang Wen, Xiuling Wu, Yuanping Hu, Xiaohua Zhang, Xiuzhi Duan, Xiucui Han, Zhihua Tao
PCA3 (prostate cancer antigen 3) gene is one of the most prostate cancer-specific genes at present. Consequently, the prostate-specific expression and the sharp up-regulation of PCA3 mRNA in prostate cancer suggest a unique transcriptional regulation, which possibly can be attributed to promoter polymorphism. In our study, we evaluated whether there is polymorphism in PCA3 promoter region and also assess the association of the polymorphism with prostate cancer. Methodology/Principal Findings
We designed a specific primer set to screen the promoter of PCA3 gene by polymerase chain reaction (PCR)-based cloning and sequencing with the DNA extracted from peripheral blood samples of prostate cancer (PCa) cases (n?=?186) and healthy control cases (n?=?135). Genotype-specific risks were estimated as odds ratios (ORs) with associated 95% confidence intervals (CIs) by chi-square test. Possible deviation of the genotype frequencies from controls and PCa cases expected under Hardy-Weinberg equilibrium was assessed by the chi-square test. Short tandem repeat polymorphism of TAAA was found in the promoter region of PCA3 gene, five polymorphisms and eight genotypes were identified. The eight genotypes were divided into three groups: =10TAAA, 11TAAA, =12TAAA. The group 11TAAA and =12TAAA were associated with higher relative risk for prostate cancer than group =10TAAA (OR?=?1.76, 95%CI?=?1.07–2.89[for group 11TAAA]; OR?=?5.28, 95%CI?=?1.76–15.89[for group =12TAAA]). Conclusions/Significance
The presence of the (TAAA)n short tandem repeat polymorphisms in the PCA3 promoter region may be a risk factor for prostate cancer in the Chinese population.